Compare CoMentis vs Neuronascent
Customers evaluate the quality of CoMentis's products using the following success metrics.
Overview
CoMentis is 20 yrs old and is based in United States.
CoMentis is focused on developing drugs to treat various central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company covers the research and development spectrum from initial drug design through manufacturing and clinical trials.
Neuronascent is 20 yrs old and is based in United States.
Neuronascent focuses on the discovery and development of therapies for Alzheimer's disease, depression, and stroke based on the science of neurogenesis. It provides a phenotypic screening platform that uses a pipeline of small-molecule oral regenerative candidates. Neuronascent was founded in 2004 and is based in Clarksville, Maryland.
Demo Video
Leadership
W. Scott Harkonen (Chief Executive Officer, President)
Judith Kelleher Andersson Ph D (Founder, Chief Executive Officer, President)
Investors
Sanderling Ventures, Life Science Angels
National Institute of Aging, Maryland Department of Business & Economic Development
Product
Information not available because CoMentis has not claimed their profile.
Work for CoMentis? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for CoMentis?
Claim your profile now.
Why Neuronascent beats CoMentis
Benefits
Products
NNI-362
Neuron regenerative oral therapy in human testing for Alzheimer's and potentially Parkinson's and other age-related disorders
Customers
Known Partners
Why They Buy